India's Lupin launches generic TriCor in U.S.
MUMBAI Nov 20 (Reuters) - Indian drugmaker Lupin Ltd said on Tuesday it launched a generic version of Abbott Laboratories' cholesterol lowering drug TriCor in the United States.
Lupin got its generic fenofibrate drug approved by the U.S. Food and Drug Administration last December.
Tricor tablets have annual sales of $1.26 billion in the United States, Lupin said in a statement.
Valued $4.46 billion, shares in Lupin closed 1.11 percent up at 568.15 rupees on Tuesday, when the Mumbai stock market was almost flat.
- Protesters fell Lenin statue, tell Ukraine's president 'you're next'
- Four dead in apparent Connecticut murder-suicide
- South Korea expands air defense zone to partially overlap China's |
- Singer Susan Boyle reveals she has Asperger's syndrome: paper
- Dynasty's Congress party punished in Indian state elections